Meditech says safety trial of anti-cancer drug successful MELBOURNE, May 16 AAP - Drug development company Meditech Research Ltd will move towards a Phase II trial of anti-cancer drug HyDox after the success of the Phase 1 safety trial. The company said patients with advanced stages of cancer had been safely administered progressively higher doses of HyDox in the Phase 1 trial. "This allows Meditech to begin planning design of its Phase II clinical trial of HyDox," the company said. Meditech said results of the Phase I trial were expected to be available to shareholders by the end of June. Meditech shares were 1.5 cents higher at 36.5 cents at 1314 AEST today. AAP
MTR Price at posting:
0.0¢ Sentiment: None Disclosure: Held
